In a clinical study of patients aged 50 to 84 years, Cologuard had an 87% speciﬁcity overall, excluding colorectal cancer and advanced adenomas, and including all nonadvanced adenomas, nonneoplastic findings, and negative results on colonoscopy. There was 90% specificity in participants with no findings on colonoscopy and no histopathological review.